- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03296787
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954
A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
연구 개요
상세 설명
The drug being tested in this study is called TAK-954. This study will evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
The study will enroll approximately up to 40 participants. Participants will be enrolled in one of the 5 treatment groups based on their renal impairment which will be determined based on Cockcroft and Gault (CG) equation as follows:
- Group A TAK-954 0.2 mg: Healthy Participants
- Group B TAK-954 0.2 mg: Mild Renal Impairment
- Group C TAK-954 0.2 mg: Moderate Renal Impairment
- Group D TAK-954 0.2 mg: Severe Renal Impairment or End-stage Renal Disease (ESRD) Without Hemodialysis
- Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD) With Hemodialysis
All participants in groups A to D will receive a single dose of TAK-954 and two single doses in Group E.
Enrollment in Group B (Mild) and Group E (ESRD requiring dialysis) will be based on assessment of safety and available PK data from Group C and Group D respectively.
This multi-center trial will be conducted in Czech Republic and Hungary. The overall time to participate in this study is approximately 8 weeks. Participants in Groups A to D will remain confined to clinic for 3 days. For both treatments, participants in Group E requiring dialysis will remain confined to clinic for 3 days. All participants will make a final visit to the clinic 10-14 days after receiving their last dose for a follow-up assessment.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- All participants: Male and female participants (non-childbearing potential) who are aged 18 to 75 years, inclusive, with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m^2).
- Group A: As much as possible, the healthy participants with normal renal function (creatinine clearance [CLcr] greater than or equal to [>=] 90 milliliter per minute [mL/min]) should be comparable to participants with renal impairment with respect to median age and weight (approximately 50 percent [%] of healthy participants on each side of the median age and weight of currently enrolled renally-impaired participants grouped together), sex, and race. This will be decided by the investigators in discussion with Takeda.
Groups B to E: Participants who have stable RI, defined as no clinically significant change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.
- Group B: Participants with mild RI (CLcr 60 to less than [<] 90 mL/min).
- Group C: Participants with moderate RI (CLcr 30 to <60 mL/min).
- Group D: Participants with severe RI or ESRD but not requiring dialysis (CLcr <30 mL/min).
- Group E: Participants with ESRD requiring dialysis (<15 mL/min requiring hemodialysis at least 3 times/week, and having been on the same dialysis treatment regimen for at least 1 month before trial entry).
- Participants should be on a stable drug regimen defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) before dosing with TAK-954.
Exclusion Criteria:
All participants:
- Are renal allograft recipients within 1 year of screening.
- Have a history of gastrointestinal (GI) motility disorder or intestinal obstruction.
- Have urinary incontinence without catheterization.
- Group A: Participants who, in the discretion of the investigator, have a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
Groups B to E:
- Receive dialysis other than intermittent dialysis (except Group E).
- Have renal disease secondary to hepatic disease (hepatorenal syndrome).
- At the discretion of the investigators, have any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Group A TAK-954 0.2 mg: Healthy Participants
Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 정맥주사.
|
실험적: Group B TAK-954 0.2 mg: Mild Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 정맥주사.
|
실험적: Group C TAK-954 0.2 mg: Moderate Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 정맥주사.
|
실험적: Group D TAK-954 0.2 mg: Severe Renal Impairment
Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 정맥주사.
|
실험적: Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)
Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
|
TAK-954 정맥주사.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
기간: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
기간: Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
기간: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
기간: Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; CLR: Renal Clearance for TAK-954
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 1
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 2
기간: Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2
기간: Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- TAK-954-1007
- U1111-1196-9206 (레지스트리 식별자: WHO)
- 2017-000715-16 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
탁-954에 대한 임상 시험
-
TakedaTakeda Development Center Americas, Inc.완전한
-
Millennium Pharmaceuticals, Inc.완전한
-
Neurocrine BiosciencesTakeda완전한